trending Market Intelligence /marketintelligence/en/news-insights/trending/6dGehkxaT70Gk4n-HIryRQ2 content esgSubNav
In This List

Emerald Health closes investment in Abattis Bioceuticals unit

Blog

Funding Social and Affordable Housing: A Credit Perspective

Blog

Global M&A By the Numbers: Q2 2021

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times


Emerald Health closes investment in Abattis Bioceuticals unit

Emerald Health Therapeutics Inc. completed its previously announced acquisition of a 53% interest in Northern Vine Canada Inc., a unit of Abattis Bioceuticals Corp.

Emerald Health invested C$2.5 million into Northern Vine for the ownership interest. The company will also appoint three of its four directors.

Abattis will continue to own the remaining 47% of Northern Vine.